• Molecular medicine in ophthalmic care

    Stuart Richer, O.D., Ph.D., William Stiles, M.D., Carla Thomas

    Background

    Lipofuscin is the most consistent and phylogenically constant morphologic marker of cellular aging. Autofluorescence of the A2E fluorophore within retinal pigment epithelial (RPE) lipofuscin affords the opportunity for noninvasive evaluation of age- and disease-related pathophysiological changes in the human retina. It is being used in National Eye Institute/Age-Related Eye Disease Study II to evaluate age-related macular degeneration (AMD) geographic atrophy expansion. Experiments show lipofuscin can be reversed in cell culture and animal models in heart, brain, spinal cord, and retinal tissues, using an array of antioxidants and iron chelators.

    Read Report

  • LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic agerelated macular degeneration to dietary supplementation with xanthophylls(abstract)

    Stuart Richer, O.D., Ph.D., Jenny Devenport, Ph.D., and John C. Lang, Ph.D.

    Background

    Age-related macular degeneration (ARMD) is the leading cause of vision loss in aging Western societies. The objective of the Lutein Antioxidant Supplementation Trial (LAST) was to determine whether specific dietary interventions increased macular pigment optical density (MPOD) and visual function in patients with atrophic ARMD. The current objective of LAST II is to discern those specific characteristics that increase MPOD, i.e., that might differentiate a responder from a nonresponder.

    Read Report

  • Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial)(abstract)

    Stuart Richer, O.D., Ph.D.; William Stiles, M.D., J.D.; Laisvyde Statkute, M.D.; Jose Pulido, M.D.; James Frankowski, M.S., Ph.D. candidatea,; David Rudy, M.D., M.P.H.c; Kevin Pei, B.S.; Michael Tsipursky, M.S.; and Jill Nyland, R.N.

    Background

    Age-related macular degeneration (ARMD) is the leading cause of vision loss in aging Western societies. The objective of the lutein antioxidant supplementation trial (LAST) is to determine whether nutritional supplementation with lutein or lutein together with antioxidants, vitamins, and minerals, improves visual function and symptoms in atrophic ARMD.

    Read Report

  • Treatment: For Failing Eyes, a Dose of Green

    By John O’Neill, THE NEW YORK TIMES

    Supplements containing lutein, a pigment found in dark green vegetables, improved the vision of men with age-related macular degeneration, a study has found. Age-related macular degeneration is the most common cause of vision loss in developed countries. Low levels of lutein consumption had previously been shown to be associated with higher risks for developing the disorder.

    Read Report

  • Plant Pigment May Reverse Vision Loss

    By Thomas H. Maugh II, LOS ANGELES TIMES

    Lutein, a yellow pigment found in dark green leafy vegetables like spinach, kale and collard greens, can reverse some of the symptoms of age-related macular degeneration, the leading cause of visual disability in the United States, according to a new study.

    Read Report

Next Entries »